LOAMU
SLN

Lombard Odier Asset Management (USA)’s Silence Therapeutics SLN Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-255,901
Closed -$1.15M – 334
2025
Q4 		$1.15M Sell
255,901
-1,589,047
-86% -$10.2M 0.11% 122
2025
Q3 		$7.12M Sell
1,844,948
-4,786
-0.3% -$26.6K 0.48% 35
2025
Q2 		$7.81M Hold
1,849,734
– – 0.59% 35
2025
Q1 		$4.04M Sell
1,849,734
-6,289
-0.3% -$30.7K 0.32% 52
2024
Q4 		$10.2M Sell
1,856,023
-808,054
-30% -$10.4M 0.75% 31
2024
Q3 		$36.2M Buy
2,664,077
+258,079
+11% +$4.8M 2.41% 10
2024
Q2 		$36.8M Buy
2,405,998
+17,086
+0.7% +$363K 2.72% 8
2024
Q1 		$41.6M Sell
2,388,912
-1,490,261
-38% -$32.4M 1.01% 28
2023
Q4 		$54.5M Sell
3,879,173
-178,759
-4% -$2.01M 0.99% 25
2023
Q3 		$33.7M Sell
4,057,932
-62,484
-2% -$461K 0.76% 33
2023
Q2 		$18.7M Buy
4,120,416
+161,315
+4% +$973K 0.4% 61
2023
Q1 		$20.7M Buy
3,959,101
+83,367
+2% +$983K 0.46% 48
2022
Q4 		$50.6M Sell
3,875,734
-20,861
-0.5% -$273K 1.29% 20
2022
Q3 		$35.7M Buy
3,896,595
+130,226
+3% +$1.37M 1.04% 24
2022
Q2 		$38.2M Buy
3,766,369
+134,135
+4% +$1.63M 1.47% 14
2022
Q1 		$55.7M Buy
3,632,234
+159,713
+5% +$3.18M 2.04% 11
2021
Q4 		$83M Buy
3,472,521
+2,874,380
+481% +$66.5M 3.24% 6
2021
Q3 		$10.7M Sell
598,141
-314,993
-34% -$7.53M 0.47% 38
2021
Q2 		$21.6M Sell
913,134
-285,007
-24% -$7.44M 0.86% 32
2021
Q1 		$24.4M Buy
1,198,141
+658,141
+122% +$16M 0.9% 22
2020
Q4 		$10.2M Hold
540,000
– – 0.49% 38
2020
Q3 		$8.1M Buy
+540,000
New +$9.98M 0.53% 41

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s SLN Position: Q1 2026 in Review

Lombard Odier Asset Management (USA) sold out of Silence Therapeutics (SLN) in Q1 2026, closing a stake of 255,901 shares — an estimated $1.15M sold.

Lombard Odier Asset Management (USA) first reported a position in SLN in Q3 2020 and held it in 22 quarters. The position peaked at $83M in Q4 2021. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Lombard Odier Asset Management (USA) reported no remaining Silence Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 255,901 Silence Therapeutics shares in Q1 2026, an estimated $1.15M.
  • Lombard Odier Asset Management (USA) first reported a position in Silence Therapeutics in Q3 2020 and held it in 22 quarters.
  • Lombard Odier Asset Management (USA)'s Silence Therapeutics position peaked at $83M in Q4 2021.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q1 2026, filed 15 May 2026.